Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Revenue

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2022		2021		2022		2021
Viatris collaboration agreement - Amounts receivable from Viatris	$	12,445	$	10,397	$	34,010	$	31,716

Schedule of collaborative amounts were recorded in the Company's condensed consolidated statements of operations

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2022		2021		2022		2021
Alfasigma	$	—	$	3	$	169	$	10
Viatris		6		6		18		18
Janssen		—		2,788		—		8,621
Total collaboration revenue	$	6	$	2,797	$	187	$	8,649

Summary of the reductions to R&D costs related to reimbursement payments

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2022		2021		2022		2021
Viatris	$	1,657	$	1,096	$	4,736	$	1,257
Janssen		—		2,205		—		4,730
Total reduction to R&D expense, net	$	1,657	$	3,301	$	4,736	$	5,987